[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514385":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":49,"collaborators":19,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Radiation therapy","Patient treated for metastatic cerebral lung cancer who has been treated with external beam radiotherapy such as in toto brain irradiation or stereotactic radiosurgery followed in the thoracic oncology department of Bichat Hospital.",[12],"Radiation: MRI with CEST sequence, IVIM and ASL sequence",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","MRI with CEST sequence, IVIM and ASL sequence","Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :\n\n* The CEST sequence\n* The ASL infusion sequence\n* The IVIM sequence",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Augustin Gaudemer, MD","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","01 40 25 76 13","augustin.gaudemer@aphp.fr",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},"Marie-Cécile Henry-Feugeas, MD","01 40 25 81 52","marie-cecile.henry-feugeas@aphp.fr",[34],{"facility":35,"status":36,"city":37,"state":19,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Hôpital Bichat-Claude Bernard","RECRUITING","Paris","75018","France","FR",{"type":42,"coordinates":43},"Point",[44,45],2.3488,48.85341,{"lat":45,"lon":44},[48],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100514385","contribution-of-the-cest-sequence-in-the-characterization-of-radionecrosis-of-brain-metastases-of-pulmonary-origin-100514385",false,"NCT05977803","Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin","ACROP","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Histologically proven primary lung cancer\n* Histologically proven or not brain metastases\n* Irradiated metastases\n* Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy\n* Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI\n* Patients affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Opposition to the study\n* Contraindication to MRI\n* Refusal of imaging by the patient\n* Patient with state medical aid (unless exemption from affiliation)\n* Severe cognitive impairment making informed consent impossible\n* Patients under guardianship or deprived of liberty","ALL","18 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.",[68,69,70],"Brain Metastases","Radionecrosis","Pulmonary Cancer",[72],"radionecrosis, metastases,","2026-03-26",{"date":75,"type":76},"2026-03-31","ACTUAL",{"date":78,"type":76},"2024-02-15",{"date":80,"type":62},"2029-03-15",{"name":5,"class":6},1]